Phenoxyphenyl sulfone N-formylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 1, 2002, Pages 219-232

  Wada, C K ^a   Holms, J H ^a   Curtin, M L ^a   Dai, Y ^a   Florjancic, A S ^a   Garland, R B ^a   Guo, Y ^a   Heyman, H R ^a   Stacey, J R ^a   Steinman, D H ^a   Albert, D H ^a   Bouska, J J ^a   Elmore, I N ^a   Goodfellow, C L ^a   Marcotte, P A ^a   Tapang, P ^a   Morgan, D W ^a   Michaelides, M R ^a   Davidsen, S K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 518; ABT 770; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; N [1 (2,2 DIMETHYL [1,3]DIOXOLAN 4 YL) 2 (4 (4 (TRIFLUOROMETHOXYPHENOXY)PHENYLSULFONYL)ETHYL] N HYDROXYFORMAMIDE; N [2 (4,4 DIMETHYL 2,5 DIOOXOIMIDAZOLIDIN 1 YL) 1 (4' TRIFLUOROMETHOXYBIPHENYL 4 SULFONYLMETHYL)ETHYL] N HYDROXYFORMAMIDE; PRINOMASTAT; REBIMASTAT; RETROHYDROXAMIC ACID; SULFONE DERIVATIVE; SULFONE N FORMYLHYDROXYLAMINE; TANOMASTAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; MELANOMA; MELANOMA CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE; FORMAMIDES; HYDROXYLAMINES; MACACA FASCICULARIS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037011911     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0103920     Document Type: Article

References (31)

1. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis
2. Development of matrix metalloproteinase inhibitors in cancer therapy
3. Recent advances in matrix metalloproteinase inhibitors research
4. Design and therapeutic application of matrix metalloproteinase inhibitors
5. Ongoing trials with matrix metalloproteinase inhibitors
6. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor
7. Experimental metastasis is suppressed in MMP-9-deficient mice
8. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
9. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor
10. The NMR structure of the inhibited catalytic domain of human stromelysin-1
11. ABT-770: A novel, selective gelatinase A inhibitor with antitumor activity in preclinical models of tumor growth
12. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
13. Preclinical pharmacology of ABT-518, a novel and potent inhibitor of gelatinase A and B with antitumor activity
14. 10-Thiaanthracenes. Part 3. A re-examination of the reaction of 9-phenylthioxanthylium salt and phenyllithium
15. The insertion and extrusion of heterosulfur bridges. VI. Comparative desulfurizations of dibenzothiophene and biphenylthiols
16. m-Thiocresol
17. Palladium-catalyzed cross-coupling reactions of organoboron compounds
18. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones
19. Chemistry of amine-boranes. Part 5. Reduction of oximes, O-Acyl-oximes, and O-Alkyl-oximes with pyridine-borane in acid
20. Acetic formic anhydride
21. Antipicornavirus activity of substituted phenoxybenzenes and phenoxypyridines
22. Synthesis of substituted heterocycles. Simple method for the introduction of the N-hydroxyurea functionality
23. First general method for direct formylation of kinetically generated ketone enolates
24. 2,2,2-Trifluoroethyl formate: A versatile and selective reagent for the formylation of alcohols, amines and N-hydroxylamines
25. Efficient large scale synthesis of matrix metalloprotease inhibitor, ABT-518
26. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors
27. Characterization of matrix metalloproteinase inhibitors: Enzymatic Assays
28. Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors
29. Enhancement of the surface expression of tumor necrosis factor α (TNFα) But not the p55 TNFα receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors
30. Inhibition of the metastatic spread and growth of B16-BL6 Murine melanoma by a synthetic matrix metalloproteinase inhibitor